Activated T cells armed with bispecific antibodies kill tumor targets.

Abstract

PURPOSE OF REVIEW:

Adoptive T-cell therapy has become one of the most exciting fields of cancer therapy in the past few years. In this article, we describe a method which combines adoptive T-cell therapy with antibody therapy by arming T cells from cord blood, normal patients, and cancer patients with bispecific antibodies capable of binding to tumor-associated antigens on one side of the bispecific antibody construct and T cells on another side of the construct. This approach redirects T cells against tumor cells in a non-MHC-restricted manner.

RECENT FINDINGS:

Various methods for manipulating the immune system including check-point inhibitors, chimeric antigen receptor T cells, and bispecific antibodies have shown promising activity in treating both hematological malignancies and solid tumors with excellent success. In recent studies, activated T cells armed with bispecific antibodies have shown good preclinical activity, safety, and promising efficacy in the clinical trials.

SUMMARY:

Activated T cells armed with bispecific antibodies represent a promising treatment for cancer immunotherapy.

• Authors: Divaya Bhutani, Lawrence G Lum
• Journal: Current opinion in hematology (Curr Opin Hematol) Vol. 22 Issue 6 Pg. 476-83 (Nov 2015) ISSN: 1531-7048 [Electronic] United States
• PMID: 26457960 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Bispecific

Topics

• Antibodies, Bispecific (immunology, therapeutic use)
• Humans
• Immunotherapy, Adoptive
• Lymphocyte Activation (immunology)
• Neoplasms (immunology, pathology, therapy)
• T-Lymphocytes (cytology, immunology)